Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Analgesia Following Uterine Artery Embolization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult female patients (\>18 years of age) who are undergoing elective uterine artery embolization will be included in the study.~Exclusion Criteria:~* Exclusion criteria for the study are patient refusal to be included in the study, the presence of language barrier that inhibits proper communication with the patient~* Contraindications to regional anesthesia~* History of allergy to amide local anesthetics or narcotics~* Known hypersensitivity to pregabalin, creatinine clearance ≤ 60 mL/min~* The presence of a progressive neurological deficit~* The presence of chronic opioid analgesia~* The presence of a coagulopathy or infection, pregnancy~* Patients with cardiovascular disease~* Patients who take daily antiplatelet medications, patients with peptic ulcer disease~* History of psychiatric disorder or inability to follow study protocol.~* Dropout criteria include failed epidural analgesia, inability to tolerate side effects (nausea) from pregabalin, and the inability to contact during follow up.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pregabalin/celecoxib group (Type: ACTIVE_COMPARATOR): pregabalin/celecoxib twice a day for 13 days.
- Pregabalin/placebo group (Type: ACTIVE_COMPARATOR): pregabalin/placebo twice a day for 13 days.
- Celecoxib/placebo group (Type: ACTIVE_COMPARATOR): celecoxib/placebo twice a day for 13 days.
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo group, two placebo tablets day of surgery and twice a day for 13 days

Based on this trial design, predict the completion outcome and termination type (if applicable).